# Endothelial dysfunction in Fabry disease: retinal biomarkers link cardiac GLA gene variants with chronic inflammation

**Authors:** Timon Wallraven, Claudia Regenbogen, Roman Günthner, Andrea Ribeiro, Javier Carbajo-Lozoya, Nora Hannane, Michael Wunderle, Abdelrahman Assaf, Maciej Lech, Henner Hanssen, Lukas Streese, Derralynn Hughes, Bernhard Haller, Konstantin Kotliar, Uwe Heemann, Christoph Schmaderer

PMC · DOI: 10.1038/s41525-025-00540-1 · 2026-01-16

## TL;DR

The study finds retinal microcirculation changes in Fabry disease patients linked to heart-related gene variants and inflammation, suggesting a non-invasive way to assess cardiovascular risk.

## Contribution

This study introduces retinal vessel analysis as a novel non-invasive biomarker for cardiovascular risk in Fabry disease.

## Key findings

- FD patients showed impaired retinal microcirculation compared to healthy controls.
- Cardiac-associated GLA variants correlated with narrower retinal arterioles and higher inflammation.
- Retinal biomarkers are linked to endothelial dysfunction and cardiovascular risk in FD.

## Abstract

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by variants in the alpha-galactosidase A gene (GLA). Cardiac complications are a major cause of mortality, but the large number of variants complicate early identification of at-risk patients. In this study, we assessed the microcirculation using Retinal Vessel Analysis (RVA) in 63 FD patients age- and gender-matched to 60 healthy controls, analyzing associations between RVA parameters, cardiac involvement, and GLA variants. FD patients showed reduced venular flicker-induced dilation, narrower retinal arterioles, and a lower arteriolar-to-venular ratio. Impaired retinal microcirculation was associated with cardiac involvement, and patients with cardiac-associated GLA variants exhibited narrower retinal arterioles. Markers of inflammation and endothelial dysfunction (ED) were significantly higher in FD patients. Higher inflammatory levels correlated with altered retinal microcirculation in patients carrying cardiac-associated GLA variants. RVA detects microvascular ED in FD patients and may serve as a non-invasive biomarker for cardiovascular risk stratification. Registration:
https://clinicaltrials.gov/study/NCT06758648; Unique identifier: NCT06758648.

## Linked entities

- **Genes:** GLA (galactosidase alpha) [NCBI Gene 2717]
- **Diseases:** Fabry disease (MONDO:0010526)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, GLA (galactosidase alpha) [NCBI Gene 2717] {aka GALA}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, NLRP6 (NLR family pyrin domain containing 6) [NCBI Gene 171389] {aka AVR, CLR11.4, NALP6, NAVR, NAVR/AVR, PAN3}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}
- **Diseases:** epilepsy (MESH:D004827), autoinflammatory diseases (MESH:D056660), X-linked inherited disease (MESH:D030342), myocarditis (MESH:D009205), malignant disease (MESH:D009369), aFID (MESH:D002311), fibrosis (MESH:D005355), heart valve disease (MESH:D006349), FD (MESH:D000795), X-linked lysosomal storage disorder (MESH:D016464), CRAE (MESH:D000080346), hypertension (MESH:D006973), nicotine abuse (MESH:D014029), central nervous vascular disease (MESH:D020785), renal involvement (MESH:C565423), Stroke (MESH:D020521), VUS (MESH:D065309), cardiac hypertrophy (MESH:D006332), infection (MESH:D007239), obesity (MESH:D009765), Cardiac inflammation (MESH:D007249), hypertrophic cardiomyopathy (MESH:D002312), cardiac arrhythmia (MESH:D001145), myocardial (MESH:D009202), HC (MESH:D000067329), cardiac (MESH:D006331), hypercholesterolemia (MESH:D006937), 19S (MESH:D000094024), kidney fibrosis (MESH:D007674), renal symptom (MESH:D006030), TIA (MESH:D002546), CKD (MESH:D051436), MI myocardial infarction (MESH:D009203), ED (MESH:D014652), LVH (MESH:D017379), Impaired retinal microcirculation (MESH:D012164), microvascular abnormalities (MESH:D017566), ERDS (MESH:D007676), necrosis (MESH:D009336), coronary heart disease (MESH:D003327), DM (MESH:D009223), HF heart failure (MESH:D006333), complications (MESH:D008107), injury (MESH:D014947), glaucoma (MESH:D005901), Impaired retinal microvascular function (MESH:D012173), CVD (MESH:D002318), AD (MESH:D000544), vFID (MESH:C566004), organ damage (MESH:D000092124), damage (MESH:D020263), diabetes mellitus I or II (MESH:D003922)
- **Chemicals:** CRVE (-), NO (MESH:D009569), Creatinine (MESH:D003404), acetylcholine (MESH:D000109), globotriaosylceramide (MESH:C018549), cholesterol (MESH:D002784), glycosphingolipids (MESH:D006028), tropicamide (MESH:D014331), Phosphate (MESH:D010710)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** N215S, c.547 G > A, p.Ser126Gly

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12824269/full.md

---
Source: https://tomesphere.com/paper/PMC12824269